Premium
Increased expression of the mannose 6‐phosphate/insulin‐like growth factor‐II receptor in breast cancer cells alters tumorigenic properties in vitro and in vivo
Author(s) -
Lee Jason S.,
Weiss Jocelyn,
Martin Janet L.,
Scott Carolyn D.
Publication year - 2003
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.11453
Subject(s) - biology , cancer research , transfection , insulin like growth factor 2 receptor , receptor , mapk/erk pathway , endocrinology , growth factor , medicine , signal transduction , microbiology and biotechnology , cell culture , insulin like growth factor 1 receptor , biochemistry , genetics
The mannose 6‐phosphate/insulin‐like growth factor‐II receptor (M6P/IGF‐IIR) is thought to act as a suppressor of tumor growth by binding the mitogenic peptide IGF‐II and modulating its extracellular levels via degradation. This receptor has been found to be absent or nonfunctional in a high proportion of breast tumors as a result of LOH and mutation of the gene. In our study, we have examined the effect of increasing expression of M6P/IGF‐IIR on breast cancer cell tumorigenicity. MDA‐MB‐231 breast cancer cells stably transfected with M6P/IGF‐IIR cDNA exhibited not only a greatly reduced ability to form tumors but also a markedly reduced growth rate in nude mice. In vitro , increased M6P/IGF‐IIR expression resulted in 2‐fold reduced uptake of IGF‐II and was associated with reduced cellular invasiness and motility. Cells with increased M6P/IGF‐IIR expression exhibited reduced phosphorylation of IGF‐I receptor and p44/42 MAPK compared to vector transfectants, or wild‐type MDA‐MB‐231 cells. These results therefore suggest that M6P/IGF‐IIR levels can modulate breast cancer cell tumorigenicity by a mechanism that may involve altered IGF‐I receptor signaling. © 2003 Wiley‐Liss, Inc.